Market Overview

Moderna Analyst: Coronavirus Vaccine Will Get Approved, Clock $5B+ In Orders Over Next Few Years

Share:
Moderna Analyst: Coronavirus Vaccine Will Get Approved, Clock $5B+ In Orders Over Next Few Years

Moderna Inc (NASDAQ: MRNA) shares are surging above the $70 level for the first time since late May following sell-side commentary on its coronavirus vaccine program.

The Moderna Analyst: Jefferies analyst Michael Yee initiated coverage of Moderna with a Buy rating and $90 price target.

The Moderna Thesis: There is good probability the vaccine will work and get at least emergency approval by early 2021, Yee said in a note, citing his discussions with key opinion leaders and disclosures made by the company thus far.

Given the likelihood of demand to remain elevated in the first two years, the analyst estimates billions in sales. This is despite the sell-side remaining divided over whether Moderna will be successful in its pursuit for a coronavirus vaccine, he added.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

Key catalysts for the stock are the Phase 2 readout due in fall and potential interim Phase 3 readout by the end of the year, Yee said.

Jefferies' $90 per share price target gives Moderna a valuation of $35 billion. This is based $15 billion valuation for the stock, based on three-to-four times sales, and $15 billion to $20 billion platform value, which is supported by a pipeline consisting of 15 other candidates in the clinic, including 5-10 vaccines and 5-19 other therapeutic programs.

"$35B on MRNA if it does have a novel mRNA platform that generated a COVID vaccine in less than a year would be worthy of praise, in our view," Yee wrote in the note.

As such, the firm believes the vaccine will get approved and could do over $5 billion in orders over the next few years and the stock will head higher.

MRNA Price Action: Moderna shares were soaring 16.8% to $73.14 at the time of publication.

Latest Ratings for MRNA

DateFirmActionFromTo
Jul 2020SVB LeerinkInitiates Coverage OnMarket Perform
Jul 2020JP MorganDowngradesOverweightNeutral
Jul 2020Chardan CapitalMaintainsBuy

View More Analyst Ratings for MRNA
View the Latest Analyst Ratings

 

Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: CoronavirusAnalyst Color Health Care Price Target Initiation Top Stories Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
RBCKeyBancMaintains100.0
PRIMKeyBancMaintains20.0
LPSNKeyBancMaintains64.0
GTESKeyBancMaintains13.0
AVNSKeyBancMaintains43.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com